Intelligent drug design come of age: STI571 as the start a of a new era in cancer research and treatment

被引：0
|
作者：
Juan Carlos Lacal
机构：
来源：
Revista de Oncología | 2001年 / 3卷 / 5期
关键词：
D O I：
10.1007/BF02719881
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 230
页数：1
相关论文
共 36 条
  • [1] Cancer treatment in the STI571 era: What will change?
    Sawyers, CL
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 13S - 16S
  • [2] The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
    O'Dwyer, Michael E.
    Druker, Brian J.
    CURRENT CANCER DRUG TARGETS, 2001, 1 (01) : 49 - 57
  • [3] Imatinib mesylate (STI571; Glivec) -: a new approach in the treatment of biliary tract cancer?
    Weidmann, M
    Kreth, F
    Feisthammel, J
    Deininger, M
    Mössner, J
    Caca, K
    ANTI-CANCER DRUGS, 2003, 14 (09) : 751 - 760
  • [4] Treatment of chronic myeloid leukemia (CML) with STI571 in patients age ≥60 years.
    Cortes, J
    Talpaz, M
    O'Brien, SM
    Manero, G
    Thomas, D
    Faderl, S
    Capdeville, R
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 256B - 256B
  • [5] Imatinib mesilate (STI571; GleevecR):: A new approach in the treatment of bilary tract cancers?
    Wiedmann, MW
    Mössner, J
    Caca, K
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6244S - 6244S
  • [6] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
    Burger, H
    van Tol, H
    Boersma, AWM
    Brok, M
    Wiemer, EAC
    Stoler, G
    Nooter, K
    BLOOD, 2004, 104 (09) : 2940 - 2942
  • [7] Tyrosine kinase inhibitor STI-571 - The new wonder drug of cancer therapy
    Haydon, RC
    Zhou, L
    He, TC
    CANCER BIOLOGY & THERAPY, 2004, 3 (04) : 393 - 394
  • [8] Bypass of drug resistance by antivascular therapy with protein tyrosine kinase inhibitor, STI571, in a human prostate cancer bone metastasis model of nude mice
    Kim, S
    Yazici, S
    Uehara, H
    Busby, J
    He, J
    Fan, D
    Fidler, IJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P39 - P39
  • [9] NCCTG N0272: PHASE II TRIAL OF IMATINIB MESYLATE; (GLEEVEC; STI571) IN TREATMENT OF RECURRENT OLIGODENDROGLIOMA AND MIXED OLIGOASTROCYTOMA: A NORTH CENTRAL CANCER TREATMENT GROUP STUDY
    Jaeckle, Kurt A.
    Anderson, S. K.
    Kosel, Matt
    Sarkaria, Jann
    Brown, Paul
    Flynn, P. J.
    Buckner, Jann C.
    Galanis, Eva
    NEURO-ONCOLOGY, 2011, 13 : 89 - 89
  • [10] Nanotechnology-based intelligent drug design for cancer metastasis treatment
    Gao, Yu
    Xie, Jingjing
    Chen, Haijun
    Gu, Songen
    Zhao, Rongli
    Shao, Jingwei
    Jia, Lee
    BIOTECHNOLOGY ADVANCES, 2014, 32 (04) : 761 - 777
1234